Eylea makes sole lead in the ₩100B nAMD Tx market
By Jung, Sae-Im | translator Kim, Jung-Ju
23.03.11 05:50:34
가나다라
0
Bayer’s Eylea makes new record with annual sales of KRW 80.4 billion last year
Novartis switches sales focus from Lucentis to Beovu... raises sales in the KRW 10 billion range
Lucentis’s sales fall for 2 consecutive years to reach KRW 29.4 billion...affected by price reduction and entry of its biosimilars
▲(from the left) Eylea, Lucentis, Beovu
The sole lead held by ‘Eylea’ in the domestic macular degeneration treatment market has been further solidified last year. Also, Novartis has been aggressively promoting sales of its recently launched new drug ‘Beovu.' With Novartis focusing its sales strategy on Beovu, sales of the company’s lesser priority, 'Lucentis,’ further declined last year.
According to the market research institution IQVIA on the 11th, Korea’s macular degeneration treatment market grew by 14% YoY from KRW 111.1 billion the previous year and recorded KRW 126.3 billion last year..
Neovascular (Wet) Age-Related Macular Degeneration (nAMD) is considered one of the 3 major causes of blindness in the el
Jung, Sae-Im (same@dailypharm.com)
If you want to see the full article, please JOIN US (click)